Back to Search
SARAH ECKHARDT, MD
MD
Obstetrics & Gynecology Physician
NPI: 1801343249IndividualAccepts Medicare
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
144594(CA)
CMS Specialties
PrimaryOBSTETRICS/GYNECOLOGY
Education
VANDERBILT UNIVERSITY SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
PMID 11118470·J Clin Oncol·2000
8-other
Population pharmacokinetic model of PI-88, a heparanase inhibitor.
PMID 19633850·Cancer Chemother Pharmacol·2010
3-trial
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
PMID 19663881·Br J Pharmacol·2009
8-other
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
PMID 19652058·J Clin Oncol·2009
3-trial
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.
PMID 19259085·Br J Cancer·2009
8-other
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
PMID 19401345·Clin Cancer Res·2009
8-other
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
PMID 18618082·Invest New Drugs·2009
3-trial
Clinical applications of metabolomics in oncology: a review.
PMID 19147747·Clin Cancer Res·2009
6-review
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
PMID 19124802·J Clin Oncol·2009
6-review
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
PMID 19307945·Am J Clin Oncol·2009
3-trial
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
PMID 18723314·J Pain Symptom Manage·2009
4-observational
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
PMID 19174560·Mol Cancer Ther·2009
8-other
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
PMID 18509645·Cancer Chemother Pharmacol·2009
8-other
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
PMID 18390968·J Clin Oncol·2008
3-trial
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
PMID 18579665·Clin Cancer Res·2008
3-trial
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
PMID 18483394·Blood·2008
8-other
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
PMID 19074845·Mol Cancer Ther·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1200 N STATE ST
LOS ANGELES, CA 90089 - Phone
- (323) 409-8848
Quick Facts
- NPI
- 1801343249
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile